Benefits
White-to-brown fat conversion
L-BAIBA dose-dependently induces 'browning' of white adipose tissue (WAT) — converting energy-storing white fat cells into thermogenic brown adipose tissue (BAT) that actively burns calories to generate heat, increasing metabolic rate without stimulants.
Fat oxidation and body composition
Animal models show L-BAIBA increases free fatty acid oxidation and reduces fat mass by approximately 40% vs. control. Human bioavailability data confirms plasma L-BAIBA increases significantly within hours of oral supplementation.
Insulin sensitivity and glycogen storage
A 28-day clinical study showed MitoBurn significantly improved glycogen supercompensation after endurance exercise. L-BAIBA also improves carbohydrate tolerance and insulin sensitivity through AMPK-GLUT4 pathway activation.
Mitochondrial health
L-BAIBA stimulates mitochondrial biogenesis and promotes ketone production, improving cellular energy efficiency. These effects mirror key metabolic adaptations seen with regular endurance exercise.
Mechanism of action
PGC-1α myokine signaling
During exercise, PGC-1α activation in skeletal muscle triggers L-BAIBA synthesis and release into circulation. L-BAIBA then acts as a hormonal signal to adipose tissue, liver, and other organs — communicating that the body is in an exercise state and should optimize fat metabolism.
UCP1 upregulation in adipose tissue
L-BAIBA activates uncoupling protein 1 (UCP1) expression in white adipocytes, the defining molecular marker of brown/beige fat identity. UCP1 uncouples mitochondrial respiration from ATP synthesis, generating heat and burning calories instead.
AMPK activation and glucose metabolism
L-BAIBA activates AMPK in skeletal muscle and liver, stimulating glucose uptake via GLUT4 translocation, increasing fatty acid oxidation, and promoting glycogen supercompensation post-exercise.
Clinical trials
Randomized, double-blind, placebo-controlled crossover study of MitoBurn® (250, 500, 1,500 mg L-β-aminoisobutyric acid) vs placebo and L-valine in healthy adults. Outcomes: plasma L-BAIBA levels, kinetics. (2022)
Healthy adults. Acute crossover PK study.
All MitoBurn® doses produced dose-dependent increases in plasma L-BAIBA above baseline and above L-valine control. Establishes oral bioavailability and dosing parameters. Critical caveat: this is a PK study — does not establish clinical efficacy. Industry-funded.
Manufacturer-conducted 28-day study examining MitoBurn® supplementation effects on glycogen resynthesis and carb tolerance after endurance exercise. Note: full peer-reviewed publication may be limited; primary documentation through NNB Nutrition.
12 healthy adults (6 men, 6 women, mean age 24). Randomized, double-blind, placebo-controlled crossover; single doses of placebo, 1500 mg L-valine, or 250/500/1500 mg MitoBurn® L-BAIBA, with 5-hour PK measurements.
L-BAIBA at 250, 500, and 1500 mg doses produced significantly greater plasma concentrations vs placebo or 1500 mg L-valine. Cmax was dose-dependent (B1500: 278 µM; B500: 95 µM; B250: 63 µM). Established absorption kinetics for oral L-BAIBA supplementation. No clinically significant adverse events. Note: glycogen supercompensation claims come from preclinical mouse studies, not this trial.